Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome
Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome
The purpose of this research is to obtain data or information on the safety and effectiveness
 of low dose naltrexone (LDN) for treating the symptoms of juvenile primary fibromyalgia
 syndrome. This is a dose finding study to find whether LDN helps the symptoms of juvenile
 fibromyalgia, and at what dose it does so.
In this pilot dosage-finding and efficacy study, we will experimentally test whether LDN
 reduces the symptoms of JPFS. We will recruit 40 children with JPFS. Participants will be
 screened via the JPFS criteria of Yunus and Masi. The study will be an open-label test of
 various doses of LDN to determine whether LDN reduces JPFS symptoms, and the appropriate dose
 at which it does so. Primary endpoints will be daily pain, fatigue, and sleep.

 The protocol is designed to take 18 weeks. There are a total of 10 study visits, taking place
 approximately every 2 weeks.
Inclusion Criteria:1. Generalized musculoskeletal aching for over 3 months duration 2.
 Moderate-severe pain in 5 of 11 tender points 3. Age 7 - 17 4. Male or female Exclusion
 Criteria:1. Diagnosed rheumatic or autoimmune condition contributing to pain 2. Abnormal
 laboratory results (Rf, ANA, ESR) 3. Use of opioid analgesics in the last 6 months 4.
 Severe depression and/or anxiety as evidenced by a diagnosis of either disorder, or by
 evidence based on a clinical interview with the patient and parent at the time of
 screening. 5. Current or previous psychiatric disorder requiring hospitalization 6.
 Inability to operate Palm OS® handheld device for self-reports 7. Inability to understand
 English 8. Inability to attend sessions at Stanford lab every 3 weeks 9. Pregnancy or
 planned pregnancy, or breastfeeding 10. Abnormal liver functioning tests